Sichuan Kelun-Biotech Secures Regulatory Approval to Begin Human Trials of Dermatology Drug
MT Newswires Live
Mar 09
Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) to begin studying its SKB575 drug in human trials, according to a Hong Kong bourse filing Monday.
The firm plans to study the drug as a treatment of atopic dermatitis.
SKB575 is also known as HBM7575.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.